Leadership

Roger Jeffs
Roger Jeffs
Chief Executive Officer

Roger Jeffs retired as President and co-CEO at United Therapeutics in 2016 after a successful 18-year tenure. Dr. Jeffs joined United Therapeutics Corporation during its start-up phase in 1998 as Director of Research, Development, and Medical, and served as the company’s President and Chief Operating Officer from 2001 to 2014 and President & co-CEO from 2015-2016. While at United Therapeutics, Dr. Jeffs helped lead the IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to >20% CAGR and $1.5B annual revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization in “recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children”. Dr. Jeffs previously held positions at Amgen, Inc. and Burroughs Wellcome Co where he held roles in clinical development. Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine. Dr. Jeffs previously served on the Board of Directors for United Therapeutics, Dova Pharmaceuticals, Sangamo Therapeutics and Albireo Pharma and currently serves on the Board of Axsome Therapeutics.
Mike Kaseta
Mike Kaseta
Chief Operating Officer & Chief Financial Officer

Mr. Kaseta joined Liquidia in December 2020 as Chief Financial Officer and added the title of Chief Operating Officer in January 2024. Mr. Kaseta’s extensive background spans corporate finance, business strategy and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Therapeutics, a private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension (PAH). Previously, Mr. Kaseta served as the Chief Financial Officer at Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) and spent eleven years at Sanofi in a variety of financial roles, culminating in the Chief Financial Officer at Sanofi SA for North America Global Services and the North America Pharmaceutical Region. In this role he managed a $10 billion business covering several product launches and more than 100 products across eight therapeutic areas. Mr. Kaseta holds a BBA in accounting from James Madison University, is a CPA (inactive) licensed in the state of New Jersey, and serves as a director of Alimera Sciences, Inc. (Nasdaq: ALIM) and Bryn Pharma.
rajeev
Rajeev Saggar
Chief Medical Officer
Dr. Saggar joined Liquidia in July 2022 and oversees all aspects of research, clinical development, medical affairs, and regulatory affairs for the company. He brings more than 20 years of experience as a practicing pulmonologist and has authored more than 60 peer-reviewed publications with scientific interests including pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD). Dr. Saggar has previously served as Interim Chief of the Division of Pulmonary Critical Care at University of Arizona, College of Medicine, Phoenix and the Medical Director of the Pulmonary Hypertension and Fibrosis Programs and Lung Transplant Program at Banner University Medical Center, Phoenix. In his role at Banner Medical Center, he served as a Principal Investigator in the pivotal INSPIRE study of YUTREPIA initiated in 2018. Just prior to joining Liquidia, Dr. Saggar served as Vice President of Clinical Development at Theravance Biopharma with oversight of all phases of clinical development across respiratory disease portfolio, including pulmonary fibrosis, allograft rejection, asthma, COPD, and COVID-19. Dr. Saggar received a M.D. degree from the University of California, Irvine. He completed his residency in Internal Medicine and fellowship in Pulmonary & Critical Care at the University of California, Irvine, as well as subspecialty training in pulmonary hypertension and lung transplantation at University of California, San Diego and University of California, Los Angeles, respectively.
Schundler
Rusty Schundler
General Counsel
Mr. Schundler serves as general counsel and corporate secretary. From 2014 to 2021, Mr. Schundler served as general counsel at PBM Capital Group, a healthcare investment firm, where he managed all legal matters for PBM and its subsidiaries. Prior to PBM, Mr. Schundler was a corporate attorney with the law firms of Woods Rogers PLC and McGuireWoods LLP from 2001 to 2014, where he specialized in mergers and acquisitions, corporate financings and general corporate matters. Mr. Schundler also served from 2011 to 2014 as adjunct faculty at the University of Virginia School of Law, where he oversaw the Transactional Law Clinic. Mr. Schundler is a member of the Virginia bar and holds a B.A. in history and economics from the University of Virginia and a J.D. from the University of Virginia School of Law.
Scott Moomaw
Scott Moomaw
Chief Commercial Officer

Mr. Moomaw joined Liquidia in November 2020 from RareGen where he held the position of Chief Operations Officer (COO) since August 2018. Mr. Moomaw is a seasoned leader in biopharmaceuticals with extensive experience launching products and developing commercial strategies and sales organizations. At RareGen he co-founded the company, built the organization, and launched Treprostinil for PAH. Prior to RareGen Mr. Moomaw was Vice President of Marketing at Opko Health. As Vice President of Marketing for United Therapeutics he had responsibility for Remodulin (parenteral Treprostinil), Tyvaso (inhaled Treprostinil), and Orenitram (oral Treprostinil) for PAH. Mr. Moomaw also held a variety of sales and marketing roles of increasing responsibility at Eli Lilly for over ten years. Mr. Moomaw holds his MBA from the University of Michigan and a Bachelor of Science (B.S.) from Miami University.
Jason Adair
Jason Adair
Chief Business Officer

As Chief Business Officer at Liquidia, Mr. Adair is responsible for corporate development activities including strategy, investor relations, communications and pursuit of collaboration and licensing opportunities for the company. Prior to joining Liquidia in 2016, Mr. Adair led business development efforts at BioCryst Pharmaceuticals as their Executive Director of Corporate Development. His work included the commercial launch and subsequent partnering of the company’s first FDA approved drug. He also worked at MedImmune/AstraZeneca in roles of increasing responsibility in business development, marketing and operations. Before entering the pharmaceutical industry, Mr. Adair worked as an analytical chemist for Syngenta and served as an officer in the United States Army. He received an M.B.A. from the Tuck School of Business at Dartmouth College and a B.S. in Chemistry from Wake Forest University.
Sarah Krepp
Sarah Krepp
Vice President, People and Culture
Mrs. Krepp joined Liquidia in June 2023 as Vice President of People and Culture. She began her career working in the genetics laboratory for Bayer (later Talecris), before transitioning into the field of human resources. She brings more than 19 years of experience in consulting, start-ups, mid-sized pharmaceuticals, and large clinical research organizations. Sarah has held progressive HR leadership roles at PRA, Salix, Chimerix, Istari Oncology, and most recently as Head of People and Culture for Fujifilm Diosynth Biotechnology. She received her B.S. in Biology from North Carolina State University and has specialized training in Executive Compensation and Organizational Psychology.